Страна: Індонезія
мова: індонезійська
Джерело: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
TRIMETAZIDINE HYDROCHLORIDE
DARYA-VARIA LABORATORIA TBK - Indonesia
TRIMETAZIDINE HYDROCHLORIDE
35 MG
TABLET PELEPASAN LAMBAT
DUS, 2 BLISTER @ 30 TABLET
DARYA-VARIA LABORATORIA TBK - Indonesia
2016-06-21
TRIZEDON ® COMPOSITION Trimetazidine dihydrochloride 35 mg. Excipients: q.s. for one modified release film-coated tablet. PHARMACEUTICAL FORM Modified release film-coated tablet. THERAPEUTIC INDICATION Adjunctive to established antiangina. Should not be used as monotherapy. POSOLOGY AND METHOD OF ADMINISTRATION Oral route The dose is one tablet of 35mg of trimetazidine twice daily during meals. The benefit of the treatment should be assessed after three months and trimetazidine should be discontinued if there is no treatment response. Special populations _Patients with renal impairment _ In patients with moderate renal impairment (creatinine clearance [30- 60] ml/min) (see _Special _ _warnings _ _and _ _precautions _ _for _ _use_ and _Pharmacokinetic properties_), the recommended dose is 1 tablet of 35mg in the morning during breakfast. _Elderly patients _ Elderly patients may have increased trimetazidine exposure due to age- related decrease in renal function (see section _Pharmacokinetic _ _properties_). In patients with moderate renal impairment (creatinine clearance [30-60] ml/min), the recommended dose is 1 tablet of 35mg in the morning during breakfast. Dose titration in elderly patients should be exercised with caution (see _Special warnings and precautions for use_). _Paediatric population: _ The safety and efficacy of trimetazidine in children aged below 18 years have not been established. No data are available. CONTRAINDICATIONS • Hypersensitivity to the active substance or to any of the excipients. • Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders, • Severe renal impairment (creatinine clearance < 30 ml/min) • Use of this drug in nursing mothers is generally inadvisable. SPECIAL WARNINGS AND PRECAUTIONS FOR USE This drug is not a curative treatment for angina attacks, nor is it indicated as an initial treatment for unstable angina, nor myocardial infarction, nor in the pre-hospital phase or during the first days of hospitalisation. Прочитайте повний документ